myeloproliferative neoplasms (MPN) | Aplastic Anemia & MDS International Foundation Return to top.

myeloproliferative neoplasms (MPN)

Katherine Tarlock, MD

Tarlock, Katherine
Assistant Professor
Seattle Children's Hospital

Katherine Tarlock, M.D., is a board certified physician at Seattle Children’s Hospital and a UW assistant professor of pediatrics.

Dr. Tarlock believes the privilege of caring for patients and families during challenging medical diagnoses is what drew her to this field and continues to be the best part of her job. She is dedicated to advancing our understanding of leukemia and being able to offer every child and family the best care.

Dr. Tarlock earned her M.D. at Chicago Medical School. She is board certified in both Pediatrics and Pediatric Hematology/Oncology.

Robert Hasserjian, MD

Hasserjian, Robert
Director, Hematopathology Fellowship Program
Massachusetts General Hospital

Dr. Hasserjian's clinical work and research focus on myeloid neoplasia.  He has served on the Executive Committee of the Society for Hematopathology and on the Education Committee of the United States and Canadian Academy of Pathology. Dr. Hasserjian is a member of the Pathology Advisory Committee for the World Health Organization Classification of Myeloid Neoplasms. Dr.

Remotely Administered Diet Intervention to Impact Symptom Burden in Myeloproliferative Neoplasm

Myeloproliferative Neoplasm (MPN) is a chronic blood cancer without cure. The major clinical issues in MPN are 1) an increased risk of blood clots 2) symptoms thought to be driven by chronic inflammation which in some cases can be debilitating and 3) progression to acute leukemia. Our current management of MPN focuses on preventing blood clots and relieving symptoms. However, treatments that reduce symptoms such as JAK inhibitors are limited to late stage MPN patients and have significant side effects including immunosuppression, reduction in platelets, and increased risk of skin cancer.

Share with addtoany.com.